TL;DR
Adult survivors of childhood cancer experience a high prevalence of insomnia, which is significantly associated with poorer neurocognitive function across multiple domains, including memory, attention, and processing speed. This suggests that addressing insomnia could be a crucial intervention to improve the cognitive well-being of this vulnerable population.
What Problem Does This Paper Address?
Childhood cancer survivors often face long-term health challenges, including neurocognitive impairments affecting areas like attention, memory, and executive functioning. While sleep disturbances are known to be common in this group, the specific impact of insomnia on their neurocognitive performance has been poorly understood. This study aims to fill that knowledge gap by investigating the association between insomnia and objectively measured neurocognitive outcomes in adult survivors of childhood cancer, distinguishing it from general sleep disturbance or daytime fatigue.
Methods
The researchers utilized data from the St. Jude Lifetime Cohort Study (SJLIFE), a large, retrospective cohort of childhood cancer survivors. Participants underwent direct assessments of neurocognitive function, covering verbal reasoning, memory, attention, processing speed, and executive functioning. Sleep quality was evaluated using the Pittsburgh Sleep Quality Index (PSQI), fatigue with the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue), and daytime sleepiness with the Epworth Sleepiness Scale (ESS).
Survivors were categorized into four groups:
- Insomnia: Defined as poor sleep efficiency (<85%) and daytime impairment (fatigue or sleepiness).
- Sleep disturbance: Defined as poor sleep efficiency (<85%) without daytime impairment.
- Daytime sleepiness or fatigue only: Defined by daytime impairment without poor sleep efficiency.
- Healthy sleepers: Defined by good sleep efficiency (>85%) and no daytime impairment.
Sex-stratified general linear models were employed to examine the associations between these sleep categories and neurocognitive performance. These models were adjusted for crucial covariates, including neurotoxic treatment exposures (e.g., cranial radiation, chemotherapy doses), chronic health conditions, age, psychological distress (anxiety, depression), physical inactivity, and pain.
Datasets
The study utilized data from the St. Jude Lifetime Cohort Study (SJLIFE). This is a well-established, dynamic cohort with prospective medical follow-up, initiated in 2007, and includes survivors of childhood cancer treated at St. Jude Children's Research Hospital. The data for this specific study were collected between February 2013 and October 2016 from 911 participants who completed in-person baseline evaluations. No new datasets were introduced.
Key Insights and Ideas
- Insomnia is a distinct neurocognitive disruptor: The study clearly differentiates insomnia (poor sleep efficiency plus daytime impairment) from general sleep disturbance or isolated daytime fatigue/sleepiness. This distinction is critical, as only insomnia showed consistent negative associations with neurocognitive performance.
- Sex differences matter: The prevalence of insomnia was higher in females, and the impact of insomnia on neurocognitive function also showed some sex-specific patterns, highlighting the need for sex-stratified analyses.
- Broad impact on cognition: Insomnia wasn't confined to a single cognitive domain; it was associated with deficits across verbal reasoning, memory, attention, executive function, and processing speed. This suggests a pervasive negative effect.
- Potential for intervention: The findings strongly suggest that treating insomnia in childhood cancer survivors could be a viable strategy to improve their cognitive functioning and overall quality of life.
Key Results
- Prevalence: Insomnia was reported by 17.4% of the total survivor sample. Females had a higher prevalence (22.1%) compared to males (12.3%).
- Neurocognitive Associations (after adjustment for treatment exposures):
- Males: Insomnia was associated with approximately a half to a full standard deviation (SD) worse performance on measures of verbal learning, short-term and long-term verbal memory, sustained attention, and cognitive fluency.
- Females: Insomnia was associated with approximately a third to a half SD worse performance on measures of verbal reasoning, memory span, sustained attention, and cognitive flexibility.
- Comparison to other sleep issues: Sleep disturbance alone (without daytime impairment) was associated with poorer neurocognitive performance on only a few measures, and daytime fatigue or sleepiness alone showed no consistent associations.
- Robustness of findings: These associations remained significant even after adjusting for a comprehensive set of covariates, including chronic health conditions, lifestyle factors, and emotional distress.
Limitations and Future Work
- Cross-sectional design: The study's cross-sectional nature prevents definitive conclusions about causality. While previous research supports disrupted sleep causing cognitive impairment, the reverse or bidirectional relationship in this specific population remains to be fully explored.
- Single-institution recruitment: Participants were recruited from a single institution and for an intervention study targeting sleep and cognition, which may limit the generalizability of the findings.
- Self-reported sleep disorders: The study relied on self-report for sleep issues. While the PSQI is a validated tool, it doesn't capture all sleep disorders (e.g., sleep apnea, hypersomnia) which might require polysomnography or multiple sleep latency tests for full assessment.
- Future Directions: The authors emphasize the need for future research to explore the causal pathways between insomnia and neurocognition, investigate the effectiveness of insomnia interventions (like CBT-I) in improving cognitive outcomes in this population, and examine sex-specific treatment approaches. They also suggest that successful insomnia treatment could lead to improvements in other aspects of health, such as anxiety and depression.
Summary updated